This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.75 Contact Hours.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.
This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Exelixis, Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Wednesday, November 8, 2017 – Friday, November 10, 2017
New York Marriott Marquis
New York, NY 10036
(800) 843-4898 | Book Online
Providing state-of-the-art cancer care through diagnostic, therapeutic, and supportive strategies is dependent on incorporating the latest clinical advancements and data into practice. In solid tumors and hematologic malignancies alike—and across all cancer types—novel approaches in testing, systemic therapy, targeted and immunotherapies, and combination strategies continue to drive improvements in patient outcomes.
Now in its 35th year, the Chemotherapy Foundation Symposium™ (CFS™) brings together more than 2000 healthcare professionals, including oncologists, hematologists, radiologists, immunologists, pharmacists, NPs, PAs, and patient advocates, and strives to deliver the latest answers to your clinical challenges. Our internationally renowned faculty will provide expert analysis on the most recent developments in cancer therapies, synthesizing scores of data to provide attendees with the critical distilled information they need. This preeminent 3-day conference provides an unparalleled opportunity to learn new methods of personalizing care for your patients with cancer. Together, we will Innovate Cancer Therapy for Tomorrow®. See you in New York!
This activity is supported by educational grants from AstraZeneca, Boehringer Ingeheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Inc., Exelixis, Ignyta, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, Taiho Oncology, and Takeda Oncology.Target Audience
This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.
Upon completion of this activity, participants should be better prepared to:
And much more!
Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/ Oncology
Co-Director, Comprehensive Breast Cancer Center Associate
Director, Clinical Investigation
University of Pittsburgh
Benjamin Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
William Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, NY
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018